On June 5, 2024, Nano-X Imaging made an announcement regarding its subsidiary Nanox AI Ltd. launching an artificial intelligence (AI) functionality in the Second Opinions online medical consultation service. Second Opinions, a platform provided by USARAD Holdings INC, connects patients with radiologists and other subspecialty physicians for additional consultation on their medical diagnoses. Three of Nanox.AI’s FDA 510(k)-cleared AI solutions have been integrated into Second Opinions, allowing patients to receive second opinions from experts in various medical and surgical subspecialties including radiology, neurology, oncology, and orthopedic surgery.
The AI solutions integrated into Second Opinions are intended to promote early detection of chronic conditions on chest and abdominal CT scans. The AI Cardiac solution (HealthCCSng) detects coronary artery calcium, the AI Bone solution (HealthOST) assesses bone mineral density and highlights vertebral spine compression fractures, and the AI Liver solution (HealthFLD) measures liver density to indicate fatty liver disease. These AI-driven insights are reviewed and approved by Second Opinions physicians and included in reports for patients who submit eligible chest and abdominal CT scans.
Erez Meltzer, Nanox Chief Executive Officer, expressed excitement about bringing AI-powered early detection through the Second Opinions platform to patients seeking peace of mind regarding their health and diagnoses. The integration of Nanox.AI’s solutions into the Second Opinions service aims to empower healthcare providers with advanced AI tools that improve patient outcomes. Nano-X Imaging is committed to exploring opportunities to leverage AI technology for accessible early diagnosis and preventative management.
For more information on Second Opinions and its new AI capabilities, visit the Artificial Intelligence (AI) Service – Second Opinions website. More information about Nano-X Imaging can be found at www.nanox.vision.